Garsorasib - Inventis Bio
Alternative Names: D-1553Latest Information Update: 06 Jun 2024
At a glance
- Originator InventisBio
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase I/II Colorectal cancer; Solid tumours
Most Recent Events
- 31 May 2024 Efficacy and adverse events data from a phase Ib/II trial in Solid tumours released by InxMed
- 31 May 2024 Suzhou Genhouse Bio in collaboration with Zhejiang Cancer Hospital plans a phase I/II trial for Solid tumors (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in July 2024 (NCT06435455)
- 05 Apr 2024 Adverse events and efficacy data from a phase I/II trial in Non-small cell lung cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)